

Table 1: Demographics: social history

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0.4%	0%	3%	7.7%	0%	0%
2	0%	0%	0%	0%	0%	0%
3	2.1%	0%	9.1%	7.7%	0%	0%
4	4.6%	14.3%	6.1%	0%	16.7%	0%
5	17.8%	14.3%	33.3%	38.5%	33.3%	0%
6	29.5%	42.9%	27.3%	23.1%	50%	50%
7	29%	14.3%	9.1%	15.4%	0%	50%
8	11.2%	14.3%	9.1%	0%	0%	0%
9	5.4%	0%	3%	7.7%	0%	0%

Table 2: Demographics: marital status

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	11.3%	28.6%	28.1%	30.8%	0%	50%
2	12.2%	14.3%	3.1%	7.7%	16.7%	0%
3	30.3%	28.6%	25%	7.7%	50%	0%
4	9.7%	7.1%	6.2%	23.1%	0%	50%
5	19.7%	7.1%	21.9%	15.4%	16.7%	0%
6	11.3%	14.3%	12.5%	7.7%	16.7%	0%
7	4.2%	0%	0%	0%	0%	0%
8	0.4%	0%	3.1%	0%	0%	0%
9	0.8%	0%	0%	7.7%	0%	0%

Table 3: Demographics: average monthly income (bearing in mind that the living expenses are different between countries)

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	8.7%	21.4%	12.9%	23.1%	16.7%	0%
2	9.2%	7.1%	3.2%	7.7%	16.7%	0%
3	16.2%	35.7%	22.6%	23.1%	33.3%	0%
4	17%	7.1%	12.9%	15.4%	0%	100%
5	25.8%	14.3%	25.8%	30.8%	0%	0%
6	14%	7.1%	9.7%	0%	16.7%	0%
7	5.7%	0%	9.7%	0%	16.7%	0%
8	2.6%	0%	3.2%	0%	0%	0%
9	0.9%	7.1%	0%	0%	0%	0%

Table 4: Demographics: type of health insurance

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	15.8%	28.6%	15.6%	23.1%	0%	50%
2	9.5%	7.1%	3.1%	7.7%	0%	0%
3	19.4%	21.4%	31.2%	15.4%	50%	0%
4	14%	14.3%	6.2%	0%	16.7%	50%
5	13.5%	7.1%	18.8%	7.7%	0%	0%
6	14.9%	14.3%	12.5%	23.1%	16.7%	0%
7	9.5%	7.1%	9.4%	7.7%	16.7%	0%
8	2.3%	0%	0%	7.7%	0%	0%
9	1.4%	0%	3.1%	7.7%	0%	0%

Table 5: Past AE treatments: previous topical treatments for AE

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0%	0%	0%	0%	0%	0%
2	0%	0%	0%	0%	0%	0%
3	0%	0%	0%	0%	0%	0%
4	1.3%	0%	2.9%	7.7%	0%	0%
5	0.4%	0%	2.9%	0%	0%	0%
6	4.6%	0%	8.8%	0%	0%	0%
7	14.2%	14.3%	29.4%	0%	0%	50%
8	25.5%	14.3%	29.4%	23.1%	16.7%	50%
9	54%	71.4%	26.5%	69.2%	83.3%	0%

Table 6: Past AE treatments: previous day hospital care treatments for AE

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0%	0%	0%	0%	0%	0%
2	0.8%	0%	0%	0%	0%	0%
3	0.4%	0%	0%	0%	0%	0%
4	2.1%	0%	3.2%	0%	0%	0%
5	2.1%	14.3%	3.2%	7.7%	0%	0%
6	9.3%	7.1%	3.2%	0%	0%	0%
7	25.3%	7.1%	48.4%	15.4%	16.7%	0%
8	19.8%	14.3%	32.3%	23.1%	33.3%	100%
9	40.1%	57.1%	9.7%	53.8%	50%	0%

Table 7: Past AE treatments: previous hospitalization for AE

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0%	0%	0%	0%	0%	0%
2	0%	0%	0%	0%	0%	0%
3	0%	0%	0%	0%	0%	0%
4	1.7%	0%	6.2%	0%	0%	0%
5	1.3%	0%	6.2%	0%	0%	0%
6	5%	14.3%	12.5%	0%	0%	0%
7	16.4%	0%	34.4%	7.7%	0%	0%
8	21%	35.7%	28.1%	23.1%	16.7%	0%
9	54.6%	50%	12.5%	69.2%	83.3%	100%

Table 8: Past AE treatments: previous structured education programme for AE

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0%	0%	0%	0%	0%	0%
2	0.8%	0%	0%	0%	0%	0%
3	1.7%	7.1%	3.1%	0%	0%	0%
4	3%	0%	3.1%	7.7%	0%	0%
5	11%	0%	6.2%	7.7%	20%	0%
6	14.8%	7.1%	34.4%	23.1%	60%	0%
7	32.9%	21.4%	21.9%	15.4%	20%	100%
8	13.1%	50%	21.9%	15.4%	0%	0%
9	22.8%	14.3%	9.4%	30.8%	0%	0%

Table 9: Past AE treatments: prior participation in trials for AE (e.g. experimental drugs)

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	2.2%	0%	0%	0%	0%	0%
2	0.4%	0%	3.4%	0%	0%	0%
3	7.5%	0%	0%	0%	0%	0%
4	6.2%	0%	6.9%	0%	20%	0%
5	14.1%	7.1%	13.8%	7.7%	0%	0%
6	15.9%	7.1%	17.2%	23.1%	0%	0%
7	23.3%	21.4%	27.6%	38.5%	0%	0%
8	13.2%	28.6%	20.7%	0%	20%	100%
9	17.2%	35.7%	10.3%	30.8%	60%	0%

Table 10: Current AE treatments: topical treatments

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0%	0%	0%	0%	0%	0%
2	0%	0%	0%	0%	0%	0%
3	0%	0%	0%	0%	0%	0%
4	0.4%	0%	0%	0%	0%	0%
5	0%	0%	0%	0%	0%	0%
6	2.1%	0%	3%	0%	0%	0%
7	5.9%	0%	9.1%	0%	0%	0%
8	10.5%	14.3%	30.3%	15.4%	16.7%	0%
9	81%	85.7%	57.6%	84.6%	83.3%	100%

Table 11: Current AE treatments: percentage of vaseline in creams

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	10.9%	9.1%	6.7%	0%	0%	0%
2	8.7%	9.1%	0%	0%	0%	0%
3	24.5%	0%	6.7%	11.1%	33.3%	0%
4	11.4%	0%	13.3%	11.1%	16.7%	0%
5	14.4%	45.5%	13.3%	22.2%	50%	0%
6	11.8%	18.2%	26.7%	33.3%	0%	0%
7	9.6%	18.2%	23.3%	11.1%	0%	0%
8	3.1%	0%	10%	0%	0%	0%
9	5.7%	0%	0%	11.1%	0%	100%

Table 12: Current AE treatments: amount of topical creams/ointments used per week (gram)

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	1.3%	0%	3.1%	0%	0%	0%
2	0%	0%	0%	0%	0%	0%
3	2.2%	0%	0%	0%	0%	0%
4	1.3%	0%	6.2%	8.3%	0%	0%
5	8.3%	0%	6.2%	0%	16.7%	0%
6	10.5%	15.4%	12.5%	8.3%	0%	0%
7	16.6%	15.4%	31.2%	33.3%	50%	50%
8	24%	7.7%	18.8%	16.7%	16.7%	50%
9	35.8%	61.5%	21.9%	33.3%	16.7%	0%

Table 13: Allergy test results: delayed contact hypersensitivity patch test

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	1.3%	0%	0%	0%	0%	0%
2	1.3%	0%	0%	0%	0%	0%
3	1.7%	0%	3.1%	0%	0%	0%
4	10.2%	0%	3.1%	10%	0%	0%
5	15.7%	0%	3.1%	0%	33.3%	0%
6	26%	16.7%	15.6%	10%	16.7%	0%
7	21.3%	75%	37.5%	50%	50%	0%
8	12.3%	0%	25%	0%	0%	0%
9	10.2%	8.3%	12.5%	30%	0%	100%

Table 14: Allergy test results: atopy patch test

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	6.9%	0%	3.1%	0%	0%	0%
2	7.4%	0%	0%	0%	0%	0%
3	16.9%	0%	3.1%	0%	0%	0%
4	18.6%	0%	0%	22.2%	0%	0%
5	16.9%	9.1%	0%	0%	33.3%	0%
6	15.6%	27.3%	15.6%	11.1%	16.7%	0%
7	8.2%	63.6%	43.8%	33.3%	50%	0%
8	5.2%	0%	21.9%	0%	0%	0%
9	4.3%	0%	12.5%	33.3%	0%	100%

Table 15: Allergy test results: double-blind placebo-controlled food challenge

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	5.2%	0%	7.1%	0%	0%	0%
2	4.7%	0%	0%	10%	0%	0%
3	21.9%	16.7%	10.7%	20%	16.7%	0%
4	10.7%	8.3%	3.6%	0%	33.3%	0%
5	23.2%	0%	17.9%	10%	33.3%	0%
6	16.7%	50%	17.9%	10%	16.7%	0%
7	9.9%	25%	14.3%	20%	0%	0%
8	3.9%	0%	25%	10%	0%	0%
9	3.9%	0%	3.6%	20%	0%	100%

Table 16: Allergy test results: skin prick testing to foods or aeroallergens

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	1.7%	0%	6.7%	0%	0%	0%
2	3.8%	0%	0%	9.1%	0%	0%
3	12.3%	8.3%	3.3%	0%	0%	0%
4	10.2%	0%	3.3%	0%	16.7%	0%
5	17%	8.3%	3.3%	9.1%	33.3%	0%
6	20%	16.7%	16.7%	18.2%	16.7%	0%
7	20%	50%	33.3%	36.4%	33.3%	0%
8	8.1%	8.3%	23.3%	9.1%	0%	0%
9	6.8%	8.3%	10%	18.2%	0%	100%

Table 17: Allergy test results: total IgE measurements in the past

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	3.9%	0%	3.8%	0%	0%	0%
2	2.2%	0%	0%	9.1%	0%	0%
3	6.1%	0%	3.8%	9.1%	0%	0%
4	12.6%	0%	11.5%	0%	0%	0%
5	15.6%	20%	7.7%	9.1%	33.3%	0%
6	18.2%	20%	15.4%	18.2%	33.3%	0%
7	28.1%	50%	26.9%	36.4%	33.3%	0%
8	5.6%	0%	19.2%	9.1%	0%	0%
9	7.8%	10%	11.5%	9.1%	0%	100%

Table 18: Allergy test results: past specific IgE measurements to foods or aeroallergens

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	1.7%	0%	3.8%	0%	0%	0%
2	1.3%	0%	0%	10%	0%	0%
3	7.8%	0%	3.8%	0%	0%	0%
4	16.4%	0%	15.4%	0%	16.7%	0%
5	16.4%	27.3%	7.7%	10%	16.7%	0%
6	21.1%	9.1%	7.7%	10%	16.7%	0%
7	19.8%	36.4%	38.5%	40%	50%	0%
8	8.2%	9.1%	15.4%	20%	0%	0%
9	7.3%	18.2%	7.7%	10%	0%	100%

Table 19: Chronic (inflammatory) co-morbidities: inflammatory bowel disease

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	3%	0%	4%	0%	0%	0%
2	2.5%	0%	0%	0%	0%	0%
3	7.2%	0%	12%	0%	0%	0%
4	16.9%	8.3%	8%	0%	16.7%	16.7%
5	25.4%	33.3%	32%	27.3%	16.7%	16.7%
6	33.1%	25%	24%	54.5%	16.7%	16.7%
7	7.6%	25%	4%	9.1%	50%	50%
8	2.5%	0%	12%	0%	0%	0%
9	1.7%	8.3%	4%	9.1%	0%	0%

Table 20: Chronic (inflammatory) co-morbidities: rheumatoid arthritis

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	2.5%	0%	4.3%	0%	0%	0%
2	2.5%	0%	0%	0%	0%	0%
3	11.9%	0%	21.7%	0%	0%	0%
4	16.9%	9.1%	4.3%	0%	16.7%	16.7%
5	26.7%	18.2%	26.1%	27.3%	33.3%	33.3%
6	27.5%	45.5%	34.8%	63.6%	0%	0%
7	8.5%	18.2%	4.3%	0%	33.3%	33.3%
8	1.3%	0%	4.3%	0%	16.7%	16.7%
9	2.1%	9.1%	0%	9.1%	0%	0%

Table 21: Chronic (inflammatory) co-morbidities: diabetes mellitus

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	1.7%	0%	4.5%	0%	0%	0%
2	2.5%	0%	0%	0%	0%	0%
3	9.3%	8.3%	18.2%	0%	0%	0%
4	16.9%	8.3%	4.5%	0%	0%	0%
5	23.3%	33.3%	27.3%	30%	33.3%	33.3%
6	30.1%	33.3%	40.9%	60%	16.7%	16.7%
7	11.4%	16.7%	0%	0%	33.3%	33.3%
8	2.1%	0%	4.5%	0%	16.7%	16.7%
9	2.5%	0%	0%	10%	0%	0%

Table 22: Smoking/alcohol/recreational drug history: smoking history

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	1.3%	0%	6.7%	0%	0%	0%
2	1.3%	0%	3.3%	0%	0%	0%
3	2.6%	0%	13.3%	0%	0%	0%
4	6.8%	15.4%	16.7%	7.7%	0%	0%
5	10.6%	0%	30%	15.4%	33.3%	0%
6	20.4%	46.2%	16.7%	46.2%	50%	0%
7	43.4%	38.5%	3.3%	23.1%	16.7%	100%
8	8.1%	0%	10%	7.7%	0%	0%
9	5.5%	0%	0%	0%	0%	0%

Table 23: Smoking/alcohol/recreational drug history: alcohol intake

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	1.3%	0%	3.2%	0%	0%	0%
2	1.7%	0%	3.2%	0%	0%	0%
3	3%	0%	12.9%	0%	0%	0%
4	9%	14.3%	9.7%	15.4%	0%	0%
5	11.6%	0%	32.3%	15.4%	16.7%	0%
6	19.7%	28.6%	9.7%	46.2%	66.7%	50%
7	41.2%	50%	12.9%	7.7%	16.7%	50%
8	7.7%	0%	16.1%	15.4%	0%	0%
9	4.7%	7.1%	0%	0%	0%	0%

Table 24: Smoking/alcohol/recreational drug history: recreational drug history (soft drugs)

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	1.7%	0%	3.4%	0%	0%	0%
2	2.6%	0%	3.4%	0%	0%	0%
3	4.3%	14.3%	17.2%	8.3%	0%	0%
4	11.1%	7.1%	13.8%	8.3%	0%	0%
5	14.5%	0%	31%	0%	16.7%	0%
6	23.8%	35.7%	20.7%	58.3%	50%	50%
7	34.5%	42.9%	3.4%	8.3%	33.3%	50%
8	4.7%	0%	6.9%	8.3%	0%	0%
9	3%	0%	0%	8.3%	0%	0%

Table 25: Current concomitant medication (i.e. other than specific AE medication): antihistamines; oral or topical

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0%	0%	0%	0%	0%	0%
2	0%	0%	0%	0%	0%	0%
3	0%	0%	0%	0%	0%	0%
4	3.8%	0%	3.1%	0%	0%	0%
5	4.6%	0%	3.1%	0%	0%	0%
6	7.2%	0%	0%	0%	0%	0%
7	25.3%	14.3%	21.9%	8.3%	0%	0%
8	14.8%	14.3%	43.8%	16.7%	16.7%	0%
9	44.3%	71.4%	28.1%	75%	83.3%	100%

Table 26: Current concomitant medication (i.e. other than specific AE medication): topical antibiotics

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0%	0%	0%	0%	0%	0%
2	0%	0%	0%	0%	0%	0%
3	0.8%	0%	0%	0%	0%	0%
4	4.2%	0%	3.3%	0%	0%	0%
5	6.3%	0%	3.3%	0%	0%	0%
6	6.8%	0%	0%	0%	0%	0%
7	33.8%	21.4%	26.7%	0%	16.7%	50%
8	13.9%	14.3%	53.3%	33.3%	33.3%	0%
9	34.2%	64.3%	13.3%	66.7%	50%	50%

Table 27: Current concomitant medication (i.e. other than specific AE medication): oral antibiotics

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0%	0%	0%	0%	0%	0%
2	0.4%	0%	0%	0%	0%	0%
3	0.8%	0%	0%	0%	0%	0%
4	1.7%	0%	3.2%	0%	0%	0%
5	3.8%	0%	0%	0%	0%	0%
6	4.2%	7.1%	0%	0%	0%	0%
7	30.9%	28.6%	41.9%	16.7%	16.7%	50%
8	20.3%	14.3%	38.7%	16.7%	16.7%	0%
9	37.7%	50%	16.1%	66.7%	66.7%	50%

Table 28: Current concomitant medication (i.e. other than specific AE medication): allergic rhinoconjunctivitis medication

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0.4%	0%	3.3%	0%	0%	0%
2	0%	0%	0%	0%	0%	0%
3	2.1%	0%	0%	0%	0%	0%
4	6%	0%	3.3%	10%	0%	0%
5	13.6%	0%	6.7%	0%	16.7%	0%
6	18.7%	0%	6.7%	10%	0%	0%
7	21.7%	28.6%	26.7%	10%	0%	0%
8	12.8%	21.4%	36.7%	20%	16.7%	0%
9	24.7%	50%	16.7%	50%	66.7%	100%

Table 29: Current concomitant medication (i.e. other than specific AE medication): asthma medication

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0%	0%	3.3%	0%	0%	0%
2	0%	0%	0%	0%	0%	0%
3	1.3%	0%	0%	0%	0%	0%
4	3.8%	0%	10%	10%	0%	0%
5	11.5%	0%	0%	0%	0%	0%
6	18.3%	0%	6.7%	10%	0%	0%
7	31.5%	14.3%	33.3%	30%	16.7%	0%
8	11.5%	28.6%	26.7%	20%	16.7%	0%
9	22.1%	57.1%	20%	30%	66.7%	100%

Table 30: Current concomitant medication (i.e. other than specific AE medication): use of complementary and alternative therapies (e.g. vitamins; acupuncture)

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	2.2%	0%	9.7%	0%	0%	0%
2	3.5%	0%	3.2%	0%	0%	0%
3	6.5%	0%	6.5%	0%	0%	0%
4	9.1%	7.1%	22.6%	9.1%	16.7%	0%
5	18.2%	7.1%	12.9%	27.3%	0%	50%
6	27.7%	21.4%	12.9%	27.3%	16.7%	0%
7	18.6%	35.7%	22.6%	27.3%	50%	0%
8	5.6%	0%	6.5%	0%	0%	0%
9	8.7%	28.6%	3.2%	9.1%	16.7%	50%

Table 31: Current concomitant medication (i.e. other than specific AE medication): sleep medication

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	2.2%	0%	3.4%	0%	0%	0%
2	0.4%	0%	6.9%	0%	0%	0%
3	2.6%	0%	0%	9.1%	0%	0%
4	9.5%	0%	13.8%	9.1%	16.7%	0%
5	13%	7.1%	17.2%	9.1%	0%	0%
6	22.9%	7.1%	27.6%	36.4%	0%	0%
7	27.7%	57.1%	20.7%	9.1%	16.7%	50%
8	10%	7.1%	10.3%	9.1%	16.7%	0%
9	11.7%	21.4%	0%	18.2%	50%	50%

Table 32: Current concomitant medication (i.e. other than specific AE medication): immunosuppressives for other inflammatory diseases

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0.4%	0%	0%	0%	0%	0%
2	0%	0%	0%	0%	0%	0%
3	0.4%	0%	0%	0%	0%	0%
4	2.6%	0%	9.4%	0%	0%	0%
5	1.7%	0%	6.2%	0%	0%	0%
6	2.2%	7.1%	6.2%	18.2%	0%	0%
7	17.8%	21.4%	34.4%	0%	0%	0%
8	23.9%	14.3%	25%	54.5%	33.3%	0%
9	50.9%	57.1%	18.8%	27.3%	66.7%	100%

Table 33: Current concomitant medication (i.e. other than specific AE medication): antidepressants

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0.9%	0%	3.8%	0%	0%	0%
2	1.7%	0%	0%	0%	0%	0%
3	4.7%	0%	7.7%	18.2%	0%	0%
4	4.7%	0%	11.5%	9.1%	0%	0%
5	12.9%	21.4%	23.1%	0%	0%	0%
6	22.8%	14.3%	19.2%	36.4%	0%	0%
7	29.7%	42.9%	23.1%	0%	83.3%	100%
8	12.5%	0%	7.7%	18.2%	0%	0%
9	9.9%	21.4%	3.8%	18.2%	16.7%	0%

Table 34: General AE questions: use of anti-bacterial soaps; washes; shampoos

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0.9%	0%	6.7%	0%	0%	0%
2	1.7%	0%	0%	0%	0%	0%
3	3%	0%	3.3%	16.7%	0%	0%
4	5.6%	7.1%	3.3%	0%	0%	50%
5	13.8%	14.3%	6.7%	8.3%	33.3%	0%
6	22%	28.6%	26.7%	25%	33.3%	0%
7	25%	28.6%	33.3%	16.7%	33.3%	0%
8	13.4%	14.3%	10%	16.7%	0%	0%
9	14.7%	7.1%	10%	16.7%	0%	50%

Table 35: General AE questions: number of baths and/or showers taken per week

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0.9%	0%	6.2%	0%	0%	0%
2	1.7%	0%	0%	0%	0%	0%
3	3%	0%	3.1%	8.3%	0%	0%
4	4.3%	7.1%	6.2%	0%	0%	0%
5	11.6%	14.3%	9.4%	8.3%	33.3%	0%
6	15.1%	50%	12.5%	8.3%	16.7%	50%
7	31.9%	14.3%	37.5%	50%	50%	0%
8	16.4%	7.1%	21.9%	16.7%	0%	0%
9	15.1%	7.1%	3.1%	8.3%	0%	50%

Table 36: General AE questions: hours of sports per week

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	3.4%	14.3%	6.5%	9.1%	0%	0%
2	3.4%	0%	3.2%	0%	0%	0%
3	11.6%	28.6%	3.2%	18.2%	0%	0%
4	18.1%	14.3%	0%	0%	16.7%	0%
5	26.3%	28.6%	29%	18.2%	50%	50%
6	20.3%	7.1%	25.8%	45.5%	33.3%	50%
7	11.6%	7.1%	25.8%	9.1%	0%	0%
8	4.7%	0%	3.2%	0%	0%	0%
9	0.4%	0%	3.2%	0%	0%	0%

Table 37: General AE questions: hours spent immobile per week

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	5.2%	14.3%	10.3%	8.3%	0%	0%
2	7.4%	0%	0%	0%	0%	0%
3	13.9%	28.6%	3.4%	25%	0%	50%
4	14.3%	14.3%	17.2%	8.3%	33.3%	0%
5	26.4%	14.3%	13.8%	8.3%	33.3%	50%
6	16.9%	21.4%	34.5%	41.7%	33.3%	0%
7	10.4%	7.1%	10.3%	8.3%	0%	0%
8	4.3%	0%	6.9%	0%	0%	0%
9	1.3%	0%	3.4%	0%	0%	0%

Table 38: General AE questions: use of sunscreen

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	1.3%	7.1%	3.3%	0%	0%	0%
2	3%	0%	0%	0%	0%	0%
3	9.9%	0%	0%	8.3%	16.7%	0%
4	15.5%	7.1%	20%	8.3%	16.7%	50%
5	22.4%	42.9%	6.7%	25%	16.7%	0%
6	21.6%	21.4%	33.3%	41.7%	33.3%	0%
7	19%	14.3%	26.7%	0%	0%	50%
8	5.6%	7.1%	3.3%	16.7%	0%	0%
9	1.7%	0%	6.7%	0%	16.7%	0%

Table 39: General AE questions: sun avoidance

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	1.3%	7.1%	0%	0%	0%	0%
2	2.1%	0%	0%	0%	0%	0%
3	12.4%	0%	6.5%	16.7%	16.7%	0%
4	13.3%	7.1%	25.8%	0%	16.7%	0%
5	25.8%	50%	0%	25%	16.7%	0%
6	19.7%	21.4%	25.8%	41.7%	33.3%	50%
7	18%	7.1%	32.3%	0%	0%	50%
8	4.7%	7.1%	3.2%	16.7%	0%	0%
9	2.6%	0%	6.5%	0%	16.7%	0%

Table 40: General AE questions: current diet (including food avoidance)

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	1.3%	7.1%	12.9%	0%	0%	0%
2	1.7%	0%	0%	0%	0%	0%
3	6%	0%	3.2%	16.7%	0%	0%
4	10.3%	7.1%	12.9%	0%	0%	0%
5	17.7%	14.3%	6.5%	16.7%	33.3%	0%
6	17.7%	21.4%	9.7%	25%	33.3%	0%
7	27.2%	21.4%	32.3%	25%	16.7%	0%
8	9.9%	21.4%	16.1%	8.3%	16.7%	50%
9	8.2%	7.1%	6.5%	8.3%	0%	50%

Table 41: General AE questions: contact with pets

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0.9%	7.1%	6.7%	8.3%	0%	0%
2	2.1%	0%	0%	8.3%	0%	0%
3	2.6%	0%	0%	8.3%	0%	0%
4	6%	7.1%	6.7%	0%	0%	0%
5	13.7%	7.1%	10%	25%	16.7%	0%
6	21.5%	21.4%	26.7%	8.3%	33.3%	0%
7	31.8%	21.4%	16.7%	25%	33.3%	0%
8	14.6%	14.3%	13.3%	8.3%	0%	0%
9	6.9%	21.4%	20%	8.3%	16.7%	100%

Table 42: General AE questions: exposures that trigger disease flares

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0.9%	0%	6.2%	0%	0%	0%
2	0.4%	0%	0%	0%	0%	0%
3	0%	0%	0%	0%	0%	0%
4	0.9%	0%	0%	0%	0%	0%
5	3%	7.1%	0%	25%	0%	0%
6	5.6%	21.4%	9.4%	8.3%	0%	0%
7	25.9%	21.4%	37.5%	8.3%	33.3%	0%
8	25.4%	7.1%	28.1%	33.3%	16.7%	0%
9	37.9%	42.9%	18.8%	25%	50%	100%

Table 43: General AE questions: factors that improve the disease; apart from the prescribed treatment

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0.9%	0%	3.1%	0%	0%	0%
2	0.9%	0%	0%	0%	0%	0%
3	0%	0%	0%	0%	0%	0%
4	1.7%	0%	3.1%	0%	0%	0%
5	3.5%	0%	3.1%	16.7%	0%	0%
6	9.1%	42.9%	6.2%	16.7%	0%	0%
7	28.6%	7.1%	31.2%	16.7%	50%	0%
8	24.2%	7.1%	28.1%	33.3%	0%	0%
9	31.2%	42.9%	25%	16.7%	50%	100%

Table 44: General AE questions: episodes of skin infection (i.e. folliculitis; HSV (herpes simplex virus); molluscum contagiosum)

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	1.3%	0%	6.7%	0%	0%	0%
2	0%	0%	0%	0%	0%	0%
3	0%	0%	3.3%	0%	0%	0%
4	1.3%	0%	3.3%	20%	0%	0%
5	3.9%	7.1%	3.3%	0%	0%	0%
6	5.6%	28.6%	13.3%	0%	16.7%	0%
7	21.5%	21.4%	30%	30%	0%	0%
8	34.3%	14.3%	33.3%	30%	50%	50%
9	32.2%	28.6%	6.7%	20%	33.3%	50%

Table 45: General AE questions: food and/or aeroallergen sensitisation during childhood

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	1.3%	0%	3.7%	8.3%	0%	0%
2	2.1%	0%	0%	0%	0%	0%
3	3.9%	0%	0%	16.7%	0%	0%
4	5.6%	0%	0%	0%	0%	0%
5	13.7%	35.7%	14.8%	25%	0%	0%
6	23.2%	14.3%	14.8%	0%	0%	50%
7	26.2%	21.4%	40.7%	33.3%	50%	0%
8	14.6%	14.3%	22.2%	8.3%	33.3%	0%
9	9.4%	14.3%	3.7%	8.3%	16.7%	50%

Table 46: General AE questions: coping strategies

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	2.6%	7.1%	3.2%	0%	0%	0%
2	0.9%	0%	0%	0%	0%	0%
3	3.9%	0%	3.2%	8.3%	0%	0%
4	6.9%	0%	3.2%	8.3%	0%	0%
5	10.8%	21.4%	6.5%	16.7%	0%	0%
6	27.7%	14.3%	12.9%	8.3%	66.7%	0%
7	20.8%	14.3%	45.2%	33.3%	33.3%	0%
8	14.7%	21.4%	9.7%	25%	0%	100%
9	11.7%	21.4%	16.1%	0%	0%	0%

Table 47: General AE questions: body image for winter-summer differences in AE extent (drawing)

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	3.9%	7.1%	3.4%	0%	0%	0%
2	3.1%	0%	0%	0%	0%	0%
3	10%	7.1%	0%	0%	0%	0%
4	8.7%	0%	10.3%	10%	0%	0%
5	21.4%	21.4%	13.8%	40%	16.7%	0%
6	22.3%	21.4%	20.7%	10%	66.7%	100%
7	16.2%	14.3%	31%	30%	16.7%	0%
8	10%	14.3%	13.8%	0%	0%	0%
9	4.4%	14.3%	6.9%	10%	0%	0%

Table 48: General AE questions: body image of changes in AE distribution over the past 5 years (drawing)

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	3.5%	7.1%	3.7%	0%	0%	0%
2	2.6%	0%	0%	0%	0%	0%
3	11.7%	7.1%	3.7%	9.1%	0%	0%
4	9.5%	0%	7.4%	0%	0%	0%
5	25.5%	28.6%	14.8%	36.4%	50%	50%
6	23.4%	28.6%	22.2%	18.2%	33.3%	50%
7	11.3%	21.4%	29.6%	27.3%	16.7%	0%
8	8.7%	7.1%	14.8%	0%	0%	0%
9	3.9%	0%	3.7%	9.1%	0%	0%

Table 49: General AE questions: days lost from school/college/work

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	1.3%	7.1%	3.3%	7.7%	0%	0%
2	0%	0%	3.3%	0%	0%	0%
3	0.9%	0%	3.3%	0%	0%	0%
4	1.7%	0%	13.3%	0%	0%	0%
5	3%	7.1%	6.7%	7.7%	0%	50%
6	9.1%	21.4%	20%	7.7%	33.3%	50%
7	27%	35.7%	23.3%	30.8%	33.3%	0%
8	25.2%	21.4%	13.3%	30.8%	16.7%	0%
9	31.7%	7.1%	13.3%	15.4%	16.7%	0%

Table 50: General AE questions: visits to other medical specialists

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	1.7%	7.1%	3.2%	0%	0%	0%
2	0.9%	0%	6.5%	0%	0%	0%
3	3%	0%	6.5%	0%	0%	0%
4	3.9%	0%	12.9%	7.7%	0%	0%
5	8.2%	14.3%	3.2%	0%	16.7%	50%
6	23.4%	42.9%	19.4%	7.7%	0%	0%
7	28.1%	14.3%	32.3%	38.5%	66.7%	0%
8	17.3%	7.1%	12.9%	30.8%	0%	50%
9	13.4%	14.3%	3.2%	15.4%	16.7%	0%

Table 51: Baseline physical examination: Fitzpatrick skin type

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0.9%	0%	0%	0%	0%	0%
2	0.9%	0%	0%	0%	0%	0%
3	5.2%	0%	4.8%	0%	0%	0%
4	9.1%	8.3%	4.8%	25%	0%	0%
5	21.2%	8.3%	9.5%	12.5%	16.7%	100%
6	16.9%	8.3%	19%	50%	66.7%	0%
7	33.3%	50%	57.1%	12.5%	16.7%	0%
8	7.4%	8.3%	4.8%	0%	0%	0%
9	5.2%	16.7%	0%	0%	0%	0%

Table 52: Baseline physical examination: weight and height for BMI calculation

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0%	0%	10%	0%	0%	0%
2	0.4%	0%	0%	0%	0%	0%
3	1.3%	7.1%	6.7%	0%	0%	0%
4	6%	0%	10%	0%	0%	0%
5	11.5%	14.3%	23.3%	18.2%	0%	0%
6	23.1%	7.1%	30%	0%	50%	0%
7	35.5%	64.3%	16.7%	63.6%	33.3%	50%
8	14.5%	0%	3.3%	18.2%	0%	0%
9	7.7%	7.1%	0%	0%	16.7%	50%

Table 53: Baseline physical examination: blood pressure

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0.4%	0%	7.1%	0%	0%	0%
2	2.1%	0%	3.6%	0%	0%	0%
3	9.4%	7.1%	3.6%	30%	0%	0%
4	13.6%	7.1%	7.1%	0%	33.3%	0%
5	19.1%	7.1%	14.3%	20%	0%	50%
6	19.6%	14.3%	28.6%	20%	16.7%	0%
7	25.5%	57.1%	28.6%	30%	33.3%	50%
8	4.3%	0%	7.1%	0%	0%	0%
9	6%	7.1%	0%	0%	16.7%	0%

Table 54: Baseline physical examination: body temperature

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	9.8%	0%	0%	10%	0%	0%
2	4.3%	0%	7.1%	0%	0%	0%
3	44.3%	21.4%	14.3%	20%	33.3%	50%
4	16.2%	7.1%	10.7%	20%	33.3%	0%
5	11.9%	21.4%	14.3%	10%	16.7%	0%
6	6.8%	42.9%	21.4%	20%	0%	0%
7	4.3%	7.1%	17.9%	10%	0%	0%
8	0.9%	0%	7.1%	10%	0%	0%
9	1.7%	0%	7.1%	0%	16.7%	50%

Table 55: Baseline physical examination: chest (lung) auscultation

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	9%	0%	0%	11.1%	0%	0%
2	6.4%	0%	0%	0%	0%	0%
3	44.4%	45.5%	12.5%	33.3%	16.7%	0%
4	18.4%	0%	8.3%	0%	16.7%	0%
5	9.4%	9.1%	16.7%	33.3%	0%	0%
6	6%	18.2%	33.3%	0%	33.3%	0%
7	3.4%	18.2%	16.7%	11.1%	16.7%	0%
8	1.7%	9.1%	12.5%	11.1%	0%	0%
9	1.3%	0%	0%	0%	16.7%	100%

Table 56: Baseline physical examination: heart auscultation

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	10.7%	0%	0%	11.1%	0%	0%
2	10.7%	0%	4.3%	0%	0%	0%
3	49.6%	54.5%	17.4%	33.3%	33.3%	0%
4	15.4%	0%	13%	11.1%	33.3%	50%
5	5.6%	0%	13%	22.2%	0%	0%
6	2.1%	18.2%	26.1%	11.1%	16.7%	0%
7	4.3%	18.2%	17.4%	0%	0%	50%
8	0.9%	9.1%	8.7%	11.1%	0%	0%
9	0.9%	0%	0%	0%	16.7%	0%

Table 57: Baseline physical examination: lymph node palpation (axillary and inguinal)

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	1.7%	0%	0%	12.5%	0%	0%
2	3%	0%	0%	0%	0%	0%
3	12.8%	0%	8.7%	25%	0%	0%
4	20.9%	25%	13%	12.5%	16.7%	0%
5	21.3%	8.3%	13%	25%	50%	0%
6	16.2%	16.7%	26.1%	0%	16.7%	0%
7	18.3%	33.3%	26.1%	12.5%	0%	0%
8	2.1%	16.7%	8.7%	12.5%	0%	0%
9	3.8%	0%	4.3%	0%	16.7%	100%

Table 58: Baseline physical examination: skin examination

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0%	0%	0%	0%	0%	0%
2	0%	0%	0%	0%	0%	0%
3	0%	0%	0%	0%	0%	0%
4	0%	0%	0%	0%	0%	0%
5	0.4%	0%	0%	0%	0%	0%
6	0.4%	0%	0%	0%	0%	0%
7	1.7%	0%	6.2%	0%	0%	0%
8	3.8%	0%	15.6%	8.3%	0%	0%
9	93.6%	100%	78.1%	91.7%	100%	100%

Table 59: Baseline physician and patient reported domains: physician-assessed clinical signs; e.g. EASI or SCORAD score

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0%	0%	0%	0%	0%	0%
2	0%	0%	0%	0%	0%	0%
3	0.4%	0%	3.8%	0%	0%	0%
4	0.9%	0%	0%	0%	0%	0%
5	2.1%	0%	0%	0%	0%	0%
6	3%	0%	0%	0%	0%	0%
7	9%	14.3%	34.6%	0%	0%	0%
8	11.2%	7.1%	7.7%	0%	0%	0%
9	73.4%	78.6%	53.8%	100%	100%	100%

Table 60: Baseline physician and patient reported domains: investigator/physician global assessment; e.g IGA

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0.9%	0%	0%	0%	0%	0%
2	0.4%	0%	0%	0%	0%	0%
3	0.9%	0%	10.7%	0%	0%	0%
4	0.9%	0%	0%	0%	0%	0%
5	4.3%	0%	7.1%	9.1%	0%	0%
6	9.5%	0%	3.6%	0%	0%	0%
7	15.5%	18.2%	39.3%	36.4%	0%	0%
8	12.9%	18.2%	25%	18.2%	0%	0%
9	54.7%	63.6%	14.3%	36.4%	100%	100%

Table 61: Baseline physician and patient reported domains: patient-reported symptoms; e.g. POEM score; itch score; sleep score

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0.9%	0%	0%	0%	0%	0%
2	0%	0%	0%	0%	0%	0%
3	0.9%	0%	0%	0%	0%	0%
4	0.4%	0%	0%	0%	0%	0%
5	0.9%	0%	0%	0%	0%	0%
6	5.2%	0%	3.3%	0%	0%	0%
7	20.4%	7.7%	26.7%	15.4%	16.7%	0%
8	12.6%	7.7%	23.3%	7.7%	16.7%	0%
9	58.7%	84.6%	46.7%	76.9%	66.7%	100%

Table 62: Baseline physician and patient reported domains: patient global assessment; e.g PGA

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0.4%	0%	0%	0%	0%	0%
2	0.4%	0%	0%	0%	0%	0%
3	1.3%	0%	0%	0%	0%	0%
4	3%	0%	0%	0%	0%	0%
5	3%	0%	3.4%	8.3%	0%	0%
6	11.7%	9.1%	13.8%	8.3%	16.7%	16.7%
7	21.2%	9.1%	31%	33.3%	0%	0%
8	16%	54.5%	27.6%	8.3%	16.7%	16.7%
9	42.9%	27.3%	24.1%	41.7%	66.7%	66.7%

Table 63: Baseline physician and patient reported domains: generic quality of life score

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	2.6%	0%	0%	0%	0%	0%
2	0.4%	0%	0%	0%	0%	0%
3	6.4%	7.7%	0%	7.7%	0%	0%
4	4.3%	0%	3.1%	0%	0%	0%
5	8.5%	0%	0%	15.4%	33.3%	0%
6	16.2%	7.7%	15.6%	0%	33.3%	0%
7	35.5%	7.7%	50%	46.2%	33.3%	0%
8	13.2%	46.2%	9.4%	15.4%	0%	0%
9	12.8%	30.8%	21.9%	15.4%	0%	100%

Table 64: Baseline physician and patient reported domains: dermatology-specific quality of life score

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0%	0%	0%	0%	0%	0%
2	0%	0%	0%	7.7%	0%	0%
3	1.7%	0%	0%	7.7%	0%	0%
4	2.1%	0%	0%	0%	0%	0%
5	1.7%	0%	3.1%	7.7%	0%	0%
6	3%	0%	3.1%	0%	0%	0%
7	23.5%	7.1%	37.5%	46.2%	33.3%	0%
8	18.8%	35.7%	31.2%	7.7%	16.7%	0%
9	49.1%	57.1%	25%	23.1%	50%	100%

Table 65: Baseline physician and patient reported domains: AE-specific quality of life score

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0.9%	0%	0%	0%	0%	0%
2	0.4%	0%	0%	0%	0%	0%
3	2.1%	0%	0%	0%	0%	0%
4	0.4%	0%	0%	0%	0%	0%
5	1.7%	0%	0%	0%	0%	0%
6	6.9%	15.4%	6.7%	0%	0%	0%
7	17.2%	7.7%	23.3%	23.1%	0%	0%
8	19.3%	7.7%	30%	15.4%	16.7%	0%
9	51.1%	69.2%	40%	61.5%	83.3%	100%

Table 66: Baseline physician and patient reported domains: patient-reported satisfaction with AE care received

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0.9%	0%	0%	0%	0%	0%
2	0.4%	0%	0%	0%	0%	0%
3	1.3%	0%	0%	0%	0%	0%
4	1.3%	0%	3%	23.1%	0%	50%
5	5.2%	7.1%	0%	7.7%	0%	0%
6	10.3%	21.4%	12.1%	15.4%	0%	0%
7	29.7%	28.6%	24.2%	23.1%	33.3%	50%
8	12.9%	14.3%	24.2%	7.7%	16.7%	0%
9	37.9%	28.6%	36.4%	23.1%	50%	0%

Table 67: Baseline physician and patient reported domains: impact of AE on the family (e.g Dermatitis Family Index questionnaire)

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0.9%	0%	0%	0%	0%	0%
2	0.4%	0%	0%	0%	0%	0%
3	1.3%	0%	0%	8.3%	0%	0%
4	1.7%	7.1%	9.7%	8.3%	0%	0%
5	8.7%	7.1%	9.7%	25%	0%	50%
6	16.6%	0%	9.7%	25%	0%	0%
7	33.6%	21.4%	35.5%	25%	33.3%	0%
8	17%	35.7%	12.9%	8.3%	66.7%	0%
9	19.7%	28.6%	22.6%	0%	0%	50%

Table 68: Baseline physician and patient reported domains: psychological score; e.g. Hospital Anxiety and Depression Scale (HADS)

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	3.5%	0%	0%	0%	0%	0%
2	1.8%	0%	0%	0%	0%	0%
3	2.6%	0%	6.9%	15.4%	0%	0%
4	4.8%	0%	3.4%	7.7%	0%	0%
5	12.7%	0%	24.1%	30.8%	0%	0%
6	17.5%	14.3%	6.9%	0%	33.3%	33.3%
7	32.9%	42.9%	34.5%	23.1%	33.3%	33.3%
8	11%	28.6%	10.3%	15.4%	33.3%	33.3%
9	13.2%	14.3%	13.8%	7.7%	0%	0%

Table 69: Baseline investigations and assessments: blood testing for past/current tuberculosis

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	7.4%	0%	4.8%	11.1%	0%	0%
2	6.1%	0%	4.8%	0%	0%	0%
3	20.3%	20%	23.8%	33.3%	33.3%	33.3%
4	16%	0%	9.5%	0%	16.7%	16.7%
5	22.5%	10%	19%	44.4%	0%	0%
6	11.3%	30%	28.6%	11.1%	16.7%	16.7%
7	9.1%	20%	4.8%	0%	16.7%	16.7%
8	3.5%	10%	4.8%	0%	16.7%	16.7%
9	3.9%	10%	0%	0%	0%	0%

Table 70: Baseline investigations and assessments: hepatitis B status

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	8.7%	0%	15.8%	25%	0%	0%
2	6.5%	0%	0%	0%	33.3%	33.3%
3	22.2%	22.2%	21.1%	0%	16.7%	16.7%
4	13.9%	11.1%	10.5%	0%	16.7%	16.7%
5	14.8%	33.3%	26.3%	62.5%	16.7%	16.7%
6	8.3%	11.1%	15.8%	12.5%	0%	0%
7	15.2%	0%	10.5%	0%	0%	0%
8	3.9%	11.1%	0%	0%	16.7%	16.7%
9	6.5%	11.1%	0%	0%	0%	0%

Table 71: Baseline investigations and assessments: hepatitis C status

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	8.7%	0%	6.2%	25%	0%	0%
2	7%	0%	0%	0%	16.7%	16.7%
3	21.7%	11.1%	31.2%	0%	33.3%	33.3%
4	13.9%	22.2%	18.8%	0%	0%	0%
5	13.5%	33.3%	18.8%	62.5%	33.3%	33.3%
6	10.4%	11.1%	12.5%	12.5%	0%	0%
7	14.3%	0%	6.2%	0%	0%	0%
8	3.5%	11.1%	6.2%	0%	16.7%	16.7%
9	7%	11.1%	0%	0%	0%	0%

Table 72: Baseline investigations and assessments: human immunodeficiency virus (HIV) status

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	5.6%	0%	5.6%	11.1%	0%	0%
2	6.9%	0%	0%	0%	0%	0%
3	13%	11.1%	16.7%	0%	33.3%	33.3%
4	13.4%	22.2%	22.2%	0%	16.7%	16.7%
5	12.6%	22.2%	22.2%	66.7%	33.3%	33.3%
6	10.8%	22.2%	22.2%	22.2%	0%	0%
7	24.2%	0%	5.6%	0%	0%	0%
8	6.1%	11.1%	5.6%	0%	16.7%	16.7%
9	7.4%	11.1%	0%	0%	0%	0%

Table 73: Baseline investigations and assessments: varicella zoster virus (VZV) immune status

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	6.9%	0%	5%	14.3%	0%	0%
2	5.2%	0%	0%	0%	16.7%	0%
3	16.4%	0%	10%	14.3%	0%	0%
4	15.5%	10%	15%	0%	33.3%	0%
5	13.4%	10%	15%	57.1%	16.7%	0%
6	13.8%	20%	45%	14.3%	16.7%	0%
7	15.1%	20%	5%	0%	0%	0%
8	6.5%	20%	5%	0%	16.7%	0%
9	7.3%	20%	0%	0%	0%	100%

Table 74: Baseline investigations and assessments: pregnancy

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	2.6%	0%	0%	25%	0%	0%
2	1.3%	0%	0%	0%	0%	0%
3	1.7%	8.3%	0%	0%	0%	0%
4	4.7%	0%	4.3%	0%	0%	0%
5	6%	0%	13%	12.5%	16.7%	0%
6	8.6%	0%	13%	0%	0%	0%
7	21.1%	25%	26.1%	0%	33.3%	0%
8	10.8%	8.3%	17.4%	0%	33.3%	0%
9	43.1%	58.3%	26.1%	62.5%	16.7%	100%

Table 75: Baseline investigations and assessments: monitoring P3NP in case of methotrexate use in adults

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	6%	0%	5.9%	0%	0%	0%
2	6%	0%	0%	0%	0%	0%
3	12.9%	0%	0%	40%	0%	0%
4	7.4%	0%	5.9%	0%	20%	20%
5	12.9%	18.2%	0%	0%	0%	0%
6	8.8%	0%	5.9%	0%	20%	20%
7	29.5%	9.1%	41.2%	20%	40%	40%
8	5.5%	9.1%	11.8%	0%	20%	20%
9	11.1%	63.6%	29.4%	40%	0%	0%

Table 76: Baseline investigations and assessments: evaluating TPMT level prior to azathioprine use

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	1.8%	0%	4.8%	0%	0%	0%
2	0.4%	0%	0%	0%	0%	0%
3	2.7%	0%	0%	0%	0%	0%
4	4.9%	0%	0%	0%	16.7%	16.7%
5	3.6%	11.1%	14.3%	20%	0%	0%
6	5.8%	0%	9.5%	0%	0%	0%
7	20.9%	0%	14.3%	20%	16.7%	16.7%
8	10.7%	33.3%	4.8%	0%	16.7%	16.7%
9	49.3%	55.6%	52.4%	60%	50%	50%

Table 77: Baseline investigations and assessments: collection of medical photographs to monitor disease extent

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	3%	0%	0%	0%	0%	0%
2	1.7%	0%	0%	0%	0%	0%
3	6%	7.7%	0%	10%	0%	0%
4	5.2%	0%	3.4%	0%	0%	0%
5	13.4%	7.7%	10.3%	0%	16.7%	16.7%
6	34.9%	15.4%	31%	40%	50%	50%
7	16.8%	30.8%	27.6%	30%	0%	0%
8	6%	23.1%	20.7%	10%	16.7%	16.7%
9	12.9%	15.4%	6.9%	10%	16.7%	16.7%

Table 78: Baseline investigations and assessments: chest radiograph

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	13.5%	0%	13.6%	22.2%	0%	0%
2	10%	0%	4.5%	0%	16.7%	16.7%
3	34.5%	50%	9.1%	22.2%	33.3%	33.3%
4	10.5%	0%	4.5%	0%	0%	0%
5	14.4%	0%	45.5%	33.3%	16.7%	16.7%
6	7.9%	25%	4.5%	22.2%	0%	0%
7	5.2%	12.5%	4.5%	0%	33.3%	33.3%
8	2.2%	12.5%	9.1%	0%	0%	0%
9	1.7%	0%	4.5%	0%	0%	0%

Table 79: Baseline investigations and assessments: urinalysis

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	13%	10%	4.5%	25%	0%	0%
2	10.4%	0%	4.5%	0%	0%	0%
3	24.7%	20%	9.1%	25%	50%	0%
4	19.5%	0%	9.1%	12.5%	0%	0%
5	15.2%	10%	40.9%	12.5%	0%	0%
6	7.8%	40%	4.5%	25%	16.7%	0%
7	6.9%	20%	13.6%	0%	16.7%	100%
8	1.3%	0%	9.1%	0%	16.7%	0%
9	1.3%	0%	4.5%	0%	0%	0%

Table 80: Baseline investigations and assessments: formal lung function testing

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	15.6%	25%	4.5%	12.5%	0%	0%
2	19.5%	0%	4.5%	0%	0%	0%
3	29.9%	25%	9.1%	25%	33.3%	0%
4	17.3%	12.5%	18.2%	0%	33.3%	0%
5	9.5%	12.5%	27.3%	37.5%	0%	0%
6	3.9%	12.5%	4.5%	12.5%	16.7%	0%
7	1.3%	12.5%	9.1%	12.5%	16.7%	0%
8	2.6%	0%	18.2%	0%	0%	0%
9	0.4%	0%	4.5%	0%	0%	100%

Table 81: Baseline investigations and assessments: skin swabs for microbiome analyses

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	5.6%	0%	0%	0%	0%	0%
2	4.7%	0%	0%	0%	0%	0%
3	11.6%	10%	0%	22.2%	16.7%	0%
4	9.9%	20%	4%	0%	33.3%	0%
5	12.5%	30%	8%	0%	0%	0%
6	15.5%	30%	36%	44.4%	33.3%	0%
7	24.6%	10%	28%	33.3%	0%	100%
8	9.9%	0%	16%	0%	0%	0%
9	5.6%	0%	8%	0%	16.7%	0%

Table 82: Baseline investigations and assessments: micronutrient measurements (e.g. vit D; ferritin; folate)

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	9.6%	0%	0%	0%	0%	0%
2	8.7%	0%	4%	11.1%	0%	0%
3	13.5%	11.1%	12%	33.3%	33.3%	33.3%
4	19.6%	0%	4%	0%	16.7%	16.7%
5	19.6%	33.3%	12%	22.2%	33.3%	33.3%
6	10.9%	44.4%	28%	22.2%	0%	0%
7	9.6%	0%	12%	11.1%	16.7%	16.7%
8	5.7%	11.1%	16%	0%	0%	0%
9	3%	0%	12%	0%	0%	0%

Table 83: Baseline investigations and assessments: barrier function measurement (e.g. TEWL)

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	10.2%	0%	0%	0%	0%	0%
2	6.7%	0%	0%	0%	0%	0%
3	12.4%	33.3%	5.3%	11.1%	33.3%	33.3%
4	8.4%	0%	5.3%	0%	50%	50%
5	18.7%	33.3%	10.5%	22.2%	16.7%	16.7%
6	16.9%	16.7%	36.8%	55.6%	0%	0%
7	14.7%	16.7%	15.8%	0%	0%	0%
8	5.3%	0%	21.1%	0%	0%	0%
9	6.7%	0%	5.3%	11.1%	0%	0%

Table 84: Baseline investigations and assessments: antibody testing (e.g. auto-antibodies (ANA; ENA or anti-drug antibodies)

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	13.2%	0%	0%	0%	0%	0%
2	8.8%	0%	0%	0%	0%	0%
3	30.3%	28.6%	5.9%	25%	50%	50%
4	16.7%	28.6%	17.6%	12.5%	33.3%	33.3%
5	15.4%	28.6%	17.6%	12.5%	16.7%	16.7%
6	9.2%	14.3%	29.4%	50%	0%	0%
7	3.9%	0%	17.6%	0%	0%	0%
8	2.6%	0%	11.8%	0%	0%	0%
9	0%	0%	0%	0%	0%	0%

Table 85: Baseline biorepository samples: collection of blood for biomarkers (e.g. TARC)

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	2.4%	0%	0%	0%	0%	0%
2	3.3%	0%	0%	0%	0%	0%
3	4.7%	12.5%	0%	0%	0%	0%
4	6.1%	0%	8%	0%	0%	0%
5	11.3%	12.5%	0%	10%	16.7%	16.7%
6	32.1%	37.5%	16%	50%	50%	50%
7	18.9%	12.5%	48%	20%	16.7%	16.7%
8	7.1%	25%	20%	0%	0%	0%
9	14.2%	0%	8%	20%	16.7%	16.7%

Table 86: Baseline biorepository samples: collection of DNA (blood or saliva) for filaggrin analysis

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	2.7%	0%	0%	0%	0%	0%
2	1.4%	0%	3.7%	0%	0%	0%
3	3.2%	0%	0%	0%	0%	0%
4	5.5%	0%	3.7%	0%	0%	0%
5	15.5%	37.5%	3.7%	0%	16.7%	16.7%
6	23.3%	25%	18.5%	40%	50%	50%
7	24.7%	0%	25.9%	30%	0%	0%
8	8.7%	37.5%	33.3%	10%	0%	0%
9	15.1%	0%	11.1%	20%	33.3%	33.3%

Table 87: Baseline biorepository samples: collection of biomaterials (e.g. DNA; PBMC; or skin biopsy) for a biorepository

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	2.8%	0%	0%	0%	0%	0%
2	3.3%	14.3%	0%	0%	0%	0%
3	1.4%	0%	0%	0%	0%	0%
4	9.4%	28.6%	0%	0%	0%	0%
5	17.8%	0%	11.5%	10%	0%	0%
6	26.3%	42.9%	26.9%	30%	50%	50%
7	14.1%	0%	34.6%	40%	0%	0%
8	10.3%	14.3%	15.4%	0%	16.7%	16.7%
9	14.6%	0%	11.5%	20%	33.3%	33.3%

Table 88: Baseline management: reasons for choosing specific treatment (systemic or phototherapy)

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0.9%	0%	0%	0%	0%	0%
2	0%	0%	0%	0%	0%	0%
3	0.4%	8.3%	3.4%	0%	0%	0%
4	0.9%	0%	0%	0%	0%	0%
5	5.2%	16.7%	3.4%	9.1%	0%	0%
6	5.6%	8.3%	10.3%	27.3%	16.7%	0%
7	28.6%	33.3%	27.6%	9.1%	0%	0%
8	26.4%	16.7%	48.3%	27.3%	50%	50%
9	32%	16.7%	6.9%	27.3%	33.3%	50%

Table 89: Baseline management: routine recording of relative contraindication(s) for selected treatment

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0.9%	0%	0%	0%	0%	0%
2	0%	0%	0%	0%	0%	0%
3	0%	0%	0%	0%	0%	0%
4	1.3%	0%	3.7%	9.1%	0%	0%
5	4.3%	16.7%	0%	0%	0%	0%
6	6.1%	8.3%	3.7%	18.2%	0%	0%
7	24.7%	66.7%	59.3%	27.3%	20%	0%
8	24.2%	8.3%	22.2%	9.1%	20%	50%
9	38.5%	0%	11.1%	36.4%	60%	50%

Table 90: FOLLOW UP general questions: 1A. minimum follow up frequency for registry data entry; once stable therapeutic dose has been reached: 2 months

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	15.4%	20%	7.4%	0%	33.3%	100%
2	4.8%	0%	7.4%	12.5%	0%	0%
3	23.7%	10%	18.5%	75%	33.3%	0%
4	19.3%	0%	22.2%	0%	16.7%	0%
5	10.5%	50%	7.4%	0%	0%	0%
6	6.6%	10%	11.1%	0%	16.7%	0%
7	10.5%	0%	18.5%	0%	0%	0%
8	1.8%	0%	3.7%	0%	0%	0%
9	7.5%	10%	3.7%	12.5%	0%	0%

Table 91: FOLLOW UP general questions: 1B. minimum follow up frequency for registry data entry; once stable therapeutic dose has been reached: 3 months

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	6.6%	9.1%	3.7%	0%	33.3%	50%
2	0.9%	0%	0%	0%	0%	0%
3	5.3%	0%	3.7%	87.5%	0%	0%
4	5.3%	0%	7.4%	0%	0%	0%
5	12.4%	27.3%	25.9%	0%	0%	0%
6	17.3%	0%	22.2%	0%	16.7%	0%
7	26.1%	36.4%	11.1%	0%	16.7%	0%
8	15.9%	18.2%	18.5%	0%	33.3%	0%
9	10.2%	9.1%	7.4%	12.5%	0%	50%

Table 92: FOLLOW UP general questions: 1C. minimum follow up frequency for registry data entry; once stable therapeutic dose has been reached: 4 months

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	15.6%	10%	11.5%	0%	33.3%	100%
2	5.8%	10%	3.8%	0%	16.7%	0%
3	10.7%	10%	11.5%	62.5%	0%	0%
4	7.6%	0%	7.7%	12.5%	16.7%	0%
5	25.4%	30%	7.7%	12.5%	0%	0%
6	17.9%	0%	38.5%	0%	0%	0%
7	10.7%	10%	11.5%	0%	16.7%	0%
8	3.6%	20%	3.8%	0%	16.7%	0%
9	2.7%	10%	3.8%	12.5%	0%	0%

Table 93: FOLLOW UP general questions: 1D. minimum follow up frequency for registry data entry; once stable therapeutic dose has been reached: 5 months

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	21.5%	20%	15.4%	0%	50%	100%
2	6.3%	10%	3.8%	0%	0%	0%
3	17%	20%	11.5%	62.5%	16.7%	0%
4	10.8%	0%	19.2%	0%	0%	0%
5	19.7%	20%	23.1%	25%	0%	0%
6	15.2%	10%	3.8%	0%	16.7%	0%
7	5.4%	0%	11.5%	0%	0%	0%
8	1.3%	10%	7.7%	0%	16.7%	0%
9	2.7%	10%	3.8%	12.5%	0%	0%

Table 94: FOLLOW UP general questions: 1E. minimum follow up frequency for registry data entry; once stable therapeutic dose has been reached: 6 months

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	12.6%	0%	11.5%	0%	0%	50%
2	4%	10%	0%	0%	0%	0%
3	7.6%	10%	11.5%	0%	0%	0%
4	4.5%	0%	0%	0%	0%	0%
5	16.6%	20%	3.8%	12.5%	0%	50%
6	11.7%	10%	7.7%	12.5%	16.7%	0%
7	15.7%	20%	26.9%	25%	0%	0%
8	12.6%	0%	30.8%	25%	83.3%	0%
9	14.8%	30%	7.7%	25%	0%	0%

Table 95: FOLLOW UP general questions: 2A. minimum follow up visits for registry data entry; after stopping photo- or systemic therapy: 3 months

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	7.1%	9.1%	3.7%	0%	0%	50%
2	0%	0%	3.7%	0%	0%	0%
3	5.3%	0%	0%	75%	0%	0%
4	3.1%	0%	3.7%	0%	0%	0%
5	12.8%	27.3%	11.1%	0%	0%	0%
6	11.9%	0%	14.8%	12.5%	16.7%	0%
7	31.9%	27.3%	29.6%	0%	50%	50%
8	12.8%	18.2%	14.8%	0%	16.7%	0%
9	15%	18.2%	18.5%	12.5%	16.7%	0%

Table 96: FOLLOW UP general questions: 2B. minimum follow up visits for registry data entry; after stopping photo- or systemic therapy: 6 months

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	9.4%	18.2%	11.5%	0%	0%	0%
2	0.9%	9.1%	3.8%	0%	0%	0%
3	2.7%	9.1%	3.8%	12.5%	0%	0%
4	3.6%	0%	0%	0%	0%	0%
5	10.7%	9.1%	11.5%	12.5%	0%	0%
6	16.5%	18.2%	15.4%	12.5%	16.7%	0%
7	21%	18.2%	19.2%	25%	50%	50%
8	26.3%	9.1%	30.8%	12.5%	33.3%	0%
9	8.9%	9.1%	3.8%	25%	0%	50%

Table 97: FOLLOW UP general questions: 2C. minimum follow up visits for registry data entry; after stopping photo- or systemic therapy: annually

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	17%	10%	14.8%	0%	0%	50%
2	4%	10%	0%	0%	0%	0%
3	6.7%	0%	7.4%	0%	0%	0%
4	5.4%	0%	11.1%	0%	0%	0%
5	12.6%	50%	11.1%	0%	0%	0%
6	10.3%	20%	3.7%	50%	16.7%	0%
7	26.5%	0%	14.8%	12.5%	50%	50%
8	6.7%	0%	25.9%	0%	33.3%	0%
9	10.8%	10%	11.1%	37.5%	0%	0%

Table 98: FOLLOW UP general questions: 2D. minimum follow up visits for registry data entry; after stopping photo- or systemic therapy: no follow up

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	66.7%	70%	45.8%	88.9%	100%	100%
2	6.4%	10%	4.2%	0%	0%	0%
3	11%	0%	12.5%	0%	0%	0%
4	3.7%	0%	12.5%	0%	0%	0%
5	5.9%	20%	4.2%	0%	0%	0%
6	0.9%	0%	4.2%	0%	0%	0%
7	1.8%	0%	0%	0%	0%	0%
8	1.8%	0%	12.5%	0%	0%	0%
9	1.8%	0%	4.2%	11.1%	0%	0%

Table 99: FOLLOW UP general questions: date of death and relation to AE

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	4.1%	0%	8.3%	0%	0%	0%
2	2.3%	0%	8.3%	0%	0%	0%
3	4.1%	0%	4.2%	0%	0%	0%
4	2.3%	18.2%	8.3%	0%	0%	0%
5	7.2%	9.1%	4.2%	0%	0%	0%
6	4.5%	9.1%	4.2%	0%	0%	0%
7	14%	9.1%	16.7%	27.3%	0%	0%
8	12.2%	9.1%	16.7%	9.1%	50%	0%
9	49.5%	45.5%	29.2%	63.6%	50%	100%

Table 100: FOLLOW UP general questions: change in diagnosis after enrolment (e.g. from AE to cutaneous T cell lymphoma (CTCL))

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	1.7%	0%	0%	0%	0%	0%
2	0.9%	0%	0%	0%	0%	0%
3	0.4%	0%	0%	0%	0%	0%
4	1.3%	0%	5.6%	0%	0%	0%
5	0.4%	0%	0%	0%	0%	0%
6	3%	8.3%	33.3%	8.3%	0%	0%
7	14.8%	16.7%	33.3%	16.7%	0%	0%
8	18.3%	33.3%	16.7%	0%	50%	0%
9	59.1%	41.7%	11.1%	75%	50%	100%

Table 101: FOLLOW UP physical examination: weight and height for BMI calculation

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	4.3%	7.7%	7.1%	9.1%	0%	0%
2	2.6%	0%	0%	0%	0%	0%
3	5.6%	0%	10.7%	9.1%	16.7%	0%
4	14.3%	7.7%	17.9%	18.2%	16.7%	0%
5	17.3%	7.7%	28.6%	27.3%	33.3%	50%
6	10.8%	7.7%	21.4%	0%	0%	50%
7	28.1%	61.5%	7.1%	27.3%	33.3%	0%
8	7.4%	0%	0%	9.1%	0%	0%
9	9.5%	7.7%	7.1%	0%	0%	0%

Table 102: FOLLOW UP physical examination: blood pressure

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	6.9%	0%	3.6%	25%	0%	0%
2	2.6%	0%	0%	0%	0%	0%
3	14.7%	7.7%	10.7%	25%	0%	0%
4	9.1%	7.7%	10.7%	0%	16.7%	0%
5	32.8%	7.7%	17.9%	37.5%	33.3%	100%
6	11.6%	38.5%	17.9%	0%	16.7%	0%
7	12.1%	23.1%	32.1%	0%	33.3%	0%
8	4.3%	7.7%	3.6%	12.5%	0%	0%
9	6%	7.7%	3.6%	0%	0%	0%

Table 103: FOLLOW UP physical examination: body temperature

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	23.4%	7.7%	0%	33.3%	0%	50%
2	8.7%	0%	3.6%	0%	0%	0%
3	35.5%	15.4%	7.1%	22.2%	16.7%	0%
4	13.4%	30.8%	14.3%	11.1%	50%	50%
5	8.2%	7.7%	3.6%	22.2%	0%	0%
6	5.2%	30.8%	14.3%	0%	16.7%	0%
7	1.7%	7.7%	46.4%	0%	16.7%	0%
8	2.2%	0%	7.1%	11.1%	0%	0%
9	1.7%	0%	3.6%	0%	0%	0%

Table 104: FOLLOW UP physical examination: chest (lung) auscultation

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	20.5%	0%	0%	30%	0%	0%
2	7%	0%	4%	0%	0%	0%
3	45.9%	20%	8%	20%	16.7%	0%
4	10.5%	40%	20%	0%	16.7%	0%
5	7%	10%	16%	40%	0%	0%
6	4.4%	10%	12%	0%	16.7%	0%
7	0.9%	10%	28%	0%	50%	0%
8	1.7%	10%	8%	10%	0%	0%
9	2.2%	0%	4%	0%	0%	100%

Table 105: FOLLOW UP physical examination: heart auscultation

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	22.7%	0%	0%	33.3%	0%	0%
2	9.6%	10%	4.2%	0%	0%	0%
3	45.9%	20%	20.8%	22.2%	33.3%	0%
4	9.2%	50%	12.5%	0%	16.7%	0%
5	4.4%	0%	12.5%	33.3%	0%	100%
6	3.9%	10%	12.5%	0%	33.3%	0%
7	1.3%	0%	33.3%	0%	16.7%	0%
8	1.7%	10%	0%	11.1%	0%	0%
9	1.3%	0%	4.2%	0%	0%	0%

Table 106: FOLLOW UP physical examination: lymph node palpation (axillary and inguinal)

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	6%	0%	0%	12.5%	0%	0%
2	3.4%	0%	0%	0%	0%	0%
3	10.3%	9.1%	12.5%	12.5%	0%	0%
4	10.3%	9.1%	4.2%	25%	16.7%	0%
5	18.1%	18.2%	20.8%	25%	16.7%	50%
6	19%	45.5%	8.3%	12.5%	50%	0%
7	21.1%	18.2%	37.5%	0%	16.7%	0%
8	7.3%	0%	8.3%	12.5%	0%	0%
9	4.3%	0%	8.3%	0%	0%	50%

Table 107: FOLLOW UP physical examination: skin examination

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0%	0%	0%	0%	0%	0%
2	0%	0%	0%	0%	0%	0%
3	0%	0%	0%	0%	0%	0%
4	0%	0%	0%	0%	0%	0%
5	0.4%	0%	0%	0%	0%	0%
6	0.4%	0%	3.2%	0%	0%	0%
7	2.2%	0%	3.2%	0%	0%	0%
8	5.7%	0%	19.4%	8.3%	0%	0%
9	91.3%	100%	74.2%	91.7%	100%	100%

Table 108: FOLLOW UP physician and patient reported domains: physician-assessed clinical signs; e.g. EASI or SCORAD score

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0.4%	0%	0%	0%	0%	0%
2	0%	0%	0%	0%	0%	0%
3	0%	0%	3.6%	0%	0%	0%
4	0.4%	0%	0%	0%	0%	0%
5	1.3%	0%	7.1%	0%	0%	0%
6	3.9%	0%	3.6%	0%	0%	0%
7	11.8%	14.3%	17.9%	15.4%	0%	0%
8	10.9%	14.3%	14.3%	23.1%	0%	0%
9	71.2%	71.4%	53.6%	61.5%	100%	100%

Table 109: FOLLOW UP physician and patient reported domains: investigator/physician global assessment; e.g IGA

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	2.2%	0%	0%	0%	0%	0%
2	0%	0%	0%	0%	0%	0%
3	1.3%	0%	0%	0%	0%	0%
4	0%	9.1%	3.8%	8.3%	0%	0%
5	4.4%	0%	7.7%	0%	0%	0%
6	7.9%	0%	7.7%	0%	0%	0%
7	17.5%	27.3%	42.3%	41.7%	0%	0%
8	13.2%	18.2%	15.4%	33.3%	0%	100%
9	53.5%	45.5%	23.1%	16.7%	100%	0%

Table 110: FOLLOW UP physician and patient reported domains: patient-reported symptoms; e.g. POEM score; itch score; sleep score

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0.4%	0%	0%	0%	0%	0%
2	0%	0%	0%	0%	0%	0%
3	1.3%	0%	0%	0%	0%	0%
4	1.3%	0%	0%	0%	0%	0%
5	2.6%	0%	7.1%	0%	0%	0%
6	5.3%	0%	7.1%	0%	0%	0%
7	19.3%	7.1%	14.3%	7.7%	16.7%	16.7%
8	10.1%	21.4%	32.1%	30.8%	16.7%	16.7%
9	59.6%	71.4%	39.3%	61.5%	66.7%	66.7%

Table 111: FOLLOW UP physician and patient reported domains: patient global assessment; e.g PGA

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	1.8%	0%	0%	0%	0%	0%
2	0.9%	0%	0%	0%	0%	0%
3	2.2%	0%	3.7%	8.3%	0%	0%
4	1.3%	0%	3.7%	0%	0%	0%
5	5.7%	0%	3.7%	0%	0%	0%
6	9.3%	16.7%	7.4%	0%	16.7%	16.7%
7	17.2%	8.3%	40.7%	33.3%	0%	0%
8	13.7%	41.7%	14.8%	41.7%	16.7%	16.7%
9	48%	33.3%	25.9%	16.7%	66.7%	66.7%

Table 112: FOLLOW UP physician and patient reported domains: generic quality of life score

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	5.6%	7.7%	0%	0%	0%	0%
2	3%	0%	0%	0%	0%	0%
3	6.5%	7.7%	3.3%	7.7%	0%	0%
4	4.7%	0%	3.3%	0%	0%	0%
5	10.8%	0%	0%	7.7%	50%	0%
6	21.6%	15.4%	26.7%	30.8%	16.7%	0%
7	24.1%	15.4%	33.3%	23.1%	33.3%	0%
8	11.6%	7.7%	16.7%	7.7%	0%	0%
9	12.1%	46.2%	16.7%	23.1%	0%	100%

Table 113: FOLLOW UP physician and patient reported domains: dermatology-specific quality of life score

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	1.3%	0%	0%	0%	0%	0%
2	1.3%	0%	0%	7.7%	0%	0%
3	0.9%	0%	0%	0%	0%	0%
4	1.7%	0%	6.7%	7.7%	0%	0%
5	2.6%	0%	3.3%	0%	0%	0%
6	5.2%	7.1%	6.7%	7.7%	0%	0%
7	19.4%	21.4%	23.3%	23.1%	33.3%	0%
8	17.2%	0%	33.3%	38.5%	33.3%	0%
9	50.4%	71.4%	26.7%	15.4%	33.3%	100%

Table 114: FOLLOW UP physician and patient reported domains: AE-specific quality of life score

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	2.6%	0%	0%	0%	0%	0%
2	0.9%	0%	0%	0%	0%	0%
3	0.9%	0%	3.3%	0%	0%	0%
4	1.3%	7.7%	3.3%	0%	0%	0%
5	3.9%	0%	0%	0%	0%	0%
6	5.7%	15.4%	0%	7.7%	0%	0%
7	19.7%	15.4%	16.7%	15.4%	0%	0%
8	14.4%	0%	36.7%	30.8%	33.3%	0%
9	50.7%	61.5%	40%	46.2%	66.7%	100%

Table 115: FOLLOW UP physician and patient reported domains: reporting of disease control (eg flares; fully controlled weeks) by physician

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	1.3%	0%	0%	0%	0%	0%
2	0%	0%	0%	0%	0%	0%
3	0%	0%	6.9%	0%	0%	0%
4	0%	0%	0%	0%	0%	0%
5	1.7%	0%	0%	0%	0%	0%
6	3.9%	15.4%	10.3%	0%	0%	0%
7	18.2%	7.7%	41.4%	33.3%	0%	0%
8	16.9%	15.4%	13.8%	25%	16.7%	0%
9	58%	61.5%	27.6%	41.7%	83.3%	100%

Table 116: FOLLOW UP physician and patient reported domains: reporting of disease control (eg flares; fully controlled weeks) by patient

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0.9%	0%	0%	0%	0%	0%
2	0%	0%	0%	0%	0%	0%
3	0%	0%	3.3%	0%	0%	0%
4	0%	0%	0%	0%	0%	0%
5	1.3%	0%	3.3%	0%	0%	0%
6	2.6%	23.1%	3.3%	0%	0%	0%
7	18.9%	0%	36.7%	33.3%	16.7%	0%
8	15.9%	15.4%	16.7%	0%	16.7%	0%
9	60.5%	61.5%	36.7%	66.7%	66.7%	100%

Table 117: FOLLOW UP physician and patient reported domains: adherence to treatment between appointments

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0%	0%	0%	0%	0%	0%
2	0.4%	0%	0%	0%	0%	0%
3	0.4%	0%	0%	0%	0%	0%
4	0.4%	0%	3%	0%	0%	0%
5	0.4%	0%	0%	0%	0%	0%
6	2.1%	0%	6.1%	0%	0%	0%
7	16.3%	0%	15.2%	30.8%	0%	50%
8	17.2%	23.1%	45.5%	23.1%	33.3%	0%
9	62.7%	76.9%	30.3%	46.2%	66.7%	50%

Table 118: FOLLOW UP physician and patient reported domains: patient-reported satisfaction with AE care received

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	0.9%	0%	0%	0%	0%	0%
2	0.4%	0%	0%	0%	0%	0%
3	0.4%	0%	0%	0%	0%	0%
4	0.9%	0%	3%	0%	0%	0%
5	3%	0%	0%	7.7%	0%	0%
6	6%	0%	9.1%	7.7%	16.7%	0%
7	24.6%	42.9%	36.4%	53.8%	33.3%	0%
8	10.8%	14.3%	15.2%	15.4%	33.3%	0%
9	53%	42.9%	36.4%	15.4%	16.7%	100%

Table 119: FOLLOW UP physician and patient reported domains: follow up socio-emotional status (open question: how are you doing?)

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	2.6%	7.7%	0%	7.7%	0%	0%
2	2.6%	0%	0%	15.4%	0%	0%
3	3%	0%	0%	15.4%	16.7%	0%
4	4.3%	0%	12.5%	7.7%	0%	0%
5	12.9%	7.7%	0%	7.7%	16.7%	50%
6	17.7%	23.1%	12.5%	15.4%	33.3%	0%
7	28.9%	7.7%	21.9%	23.1%	33.3%	0%
8	13.4%	15.4%	40.6%	7.7%	0%	0%
9	14.7%	38.5%	12.5%	0%	0%	50%

Table 120: FOLLOW UP physician and patient reported domains: daily symptom tracker

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	3.5%	7.1%	0%	0%	0%	0%
2	3.5%	0%	0%	8.3%	0%	0%
3	12.2%	0%	6.5%	25%	0%	50%
4	8.7%	14.3%	12.9%	0%	16.7%	0%
5	22.7%	14.3%	3.2%	33.3%	50%	0%
6	23.6%	21.4%	41.9%	33.3%	33.3%	0%
7	16.6%	28.6%	16.1%	0%	0%	0%
8	4.8%	7.1%	9.7%	0%	0%	50%
9	4.4%	7.1%	9.7%	0%	0%	0%

Table 121: FOLLOW UP physician and patient reported domains: impact of AE on the family (e.g Dermatitis Family Index questionnaire)

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	1.7%	0%	0%	0%	0%	0%
2	1.7%	0%	3.2%	0%	0%	0%
3	2.2%	0%	0%	23.1%	0%	0%
4	3.5%	0%	3.2%	15.4%	0%	0%
5	7.9%	7.1%	6.5%	15.4%	0%	50%
6	21%	7.1%	25.8%	7.7%	50%	0%
7	37.6%	42.9%	19.4%	38.5%	33.3%	50%
8	12.2%	14.3%	29%	0%	16.7%	0%
9	12.2%	28.6%	12.9%	0%	0%	0%

Table 122: FOLLOW UP physician and patient reported domains: psychological score (e.g. Hospital Anxiety and Depression Scale (HADS))

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	3.5%	0%	0%	0%	0%	0%
2	2.6%	0%	0%	7.7%	0%	0%
3	4.4%	0%	6.9%	15.4%	0%	0%
4	2.6%	0%	0%	7.7%	0%	0%
5	10.5%	7.1%	20.7%	15.4%	33.3%	100%
6	19.7%	14.3%	6.9%	15.4%	50%	0%
7	35.1%	35.7%	41.4%	30.8%	0%	0%
8	10.1%	28.6%	17.2%	7.7%	16.7%	0%
9	11.4%	14.3%	6.9%	0%	0%	0%

Table 123: FOLLOW UP investigations and assessments: A. minimum frequency of safety investigations: 6 weeks

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	27.1%	12.5%	19.2%	20%	0%	100%
2	5%	12.5%	7.7%	40%	0%	0%
3	13.1%	25%	23.1%	0%	0%	0%
4	9%	0%	11.5%	40%	33.3%	0%
5	17.6%	12.5%	26.9%	0%	33.3%	0%
6	8.1%	12.5%	0%	0%	16.7%	0%
7	7.7%	25%	0%	0%	0%	0%
8	4.1%	0%	3.8%	0%	0%	0%
9	8.1%	0%	7.7%	0%	16.7%	0%

Table 124: FOLLOW UP investigations and assessments: B. minimum frequency of safety investigations: 8 weeks

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	19.9%	12.5%	12%	20%	0%	100%
2	6.3%	0%	8%	20%	0%	0%
3	8.6%	12.5%	16%	0%	0%	0%
4	9.5%	0%	20%	60%	16.7%	0%
5	16.3%	25%	28%	0%	16.7%	0%
6	9.5%	0%	4%	0%	33.3%	0%
7	15.4%	25%	4%	0%	16.7%	0%
8	8.6%	25%	8%	0%	0%	0%
9	5.9%	0%	0%	0%	16.7%	0%

Table 125: FOLLOW UP investigations and assessments: C. minimum frequency of safety investigations:
10 weeks

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	26.8%	12.5%	16%	20%	0%	100%
2	5.5%	12.5%	8%	20%	0%	0%
3	9.1%	12.5%	32%	0%	0%	0%
4	11.4%	0%	8%	20%	16.7%	0%
5	14.1%	12.5%	8%	20%	33.3%	0%
6	16.8%	12.5%	12%	20%	33.3%	0%
7	10%	25%	12%	0%	0%	0%
8	4.5%	0%	4%	0%	16.7%	0%
9	1.8%	12.5%	0%	0%	0%	0%

Table 126: FOLLOW UP investigations and assessments: D. minimum frequency of safety investigations:
12 weeks

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	8.1%	0%	3.8%	20%	0%	0%
2	1.8%	0%	3.8%	0%	0%	0%
3	3.6%	0%	7.7%	0%	0%	0%
4	3.1%	0%	3.8%	0%	16.7%	0%
5	6.7%	0%	11.5%	20%	0%	0%
6	10.3%	25%	11.5%	0%	0%	0%
7	26%	25%	34.6%	20%	0%	0%
8	23.3%	0%	15.4%	20%	33.3%	0%
9	17%	50%	7.7%	20%	50%	100%

Table 127: FOLLOW UP investigations and assessments: E. minimum frequency of safety investigations: 14 weeks

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	30.6%	12.5%	16%	20%	0%	100%
2	6.8%	12.5%	16%	20%	0%	0%
3	10.5%	12.5%	20%	0%	16.7%	0%
4	11%	0%	16%	20%	16.7%	0%
5	12.8%	0%	4%	0%	33.3%	0%
6	15.1%	50%	12%	40%	16.7%	0%
7	6.4%	12.5%	4%	0%	0%	0%
8	3.7%	0%	8%	0%	16.7%	0%
9	3.2%	0%	4%	0%	0%	0%

Table 128: FOLLOW UP investigations and assessments: F. minimum frequency of safety investigations: 16 weeks

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	29.7%	12.5%	16%	0%	0%	100%
2	7.3%	12.5%	12%	20%	0%	0%
3	10.5%	12.5%	16%	0%	0%	0%
4	10%	0%	12%	40%	0%	0%
5	12.8%	25%	12%	0%	33.3%	0%
6	12.8%	12.5%	0%	0%	16.7%	0%
7	9.1%	25%	16%	20%	0%	0%
8	3.7%	0%	4%	0%	16.7%	0%
9	4.1%	0%	12%	20%	33.3%	0%

Table 129: FOLLOW UP investigations and assessments: collection of medical photographs to monitor disease extent

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	7.5%	0%	0%	0%	0%	0%
2	2.2%	0%	0%	9.1%	0%	0%
3	6.2%	0%	3.2%	0%	0%	0%
4	4.8%	0%	9.7%	0%	16.7%	16.7%
5	11.9%	27.3%	6.5%	36.4%	0%	0%
6	25.1%	18.2%	9.7%	9.1%	33.3%	33.3%
7	10.6%	18.2%	35.5%	0%	16.7%	16.7%
8	6.6%	18.2%	12.9%	27.3%	0%	0%
9	25.1%	18.2%	22.6%	18.2%	33.3%	33.3%

Table 130: FOLLOW UP investigations and assessments: test for internal cortisol production (i.e. due to adrenal suppression by oral prednisone)

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	9.6%	0%	0%	0%	0%	0%
2	7%	0%	0%	14.3%	16.7%	0%
3	12.3%	42.9%	0%	14.3%	0%	0%
4	14.5%	14.3%	4%	14.3%	16.7%	0%
5	23.2%	42.9%	8%	14.3%	16.7%	0%
6	14.5%	0%	32%	14.3%	16.7%	0%
7	11.4%	0%	32%	14.3%	16.7%	0%
8	2.6%	0%	12%	14.3%	16.7%	100%
9	4.8%	0%	12%	0%	0%	0%

Table 131: FOLLOW UP investigations and assessments: urinalysis

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	17.9%	0%	0%	28.6%	0%	0%
2	10.5%	0%	0%	0%	0%	0%
3	21.4%	33.3%	10%	28.6%	50%	0%
4	19.2%	11.1%	20%	14.3%	0%	0%
5	11.8%	44.4%	15%	0%	16.7%	0%
6	10%	11.1%	30%	0%	33.3%	100%
7	5.2%	0%	10%	14.3%	0%	0%
8	3.1%	0%	10%	14.3%	0%	0%
9	0.9%	0%	5%	0%	0%	0%

Table 132: FOLLOW UP investigations and assessments: skin swabs for microbiome analyses

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	9.6%	0%	0%	0%	0%	0%
2	6.6%	11.1%	0%	0%	0%	0%
3	5.7%	22.2%	0%	20%	16.7%	16.7%
4	11.4%	0%	4.2%	0%	66.7%	66.7%
5	14.9%	22.2%	12.5%	10%	16.7%	16.7%
6	14%	33.3%	29.2%	30%	0%	0%
7	23.2%	11.1%	37.5%	20%	0%	0%
8	7.9%	0%	16.7%	10%	0%	0%
9	6.6%	0%	0%	10%	0%	0%

Table 133: FOLLOW UP investigations and assessments: barrier function measurement (e.g. TEWL)

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	11.2%	0%	0%	0%	0%	0%
2	10.8%	0%	0%	0%	0%	0%
3	11.2%	28.6%	5%	11.1%	33.3%	33.3%
4	10.8%	0%	5%	0%	66.7%	66.7%
5	14.8%	28.6%	10%	22.2%	0%	0%
6	11.7%	42.9%	45%	33.3%	0%	0%
7	16.1%	0%	20%	22.2%	0%	0%
8	6.7%	0%	15%	0%	0%	0%
9	6.7%	0%	0%	11.1%	0%	0%

Table 134: FOLLOW UP investigations and assessments: antibody testing (e.g. auto-antibodies (ANA; ENA or anti-drug antibodies)

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	17.5%	0%	0%	0%	0%	0%
2	15.8%	0%	0%	0%	0%	0%
3	26.3%	66.7%	4.5%	42.9%	50%	50%
4	12.3%	0%	22.7%	0%	33.3%	33.3%
5	11.8%	16.7%	18.2%	0%	16.7%	16.7%
6	7.5%	16.7%	18.2%	42.9%	0%	0%
7	4.8%	0%	13.6%	14.3%	0%	0%
8	2.6%	0%	18.2%	0%	0%	0%
9	1.3%	0%	4.5%	0%	0%	0%

Table 135: FOLLOW UP biorepository samples: collection of blood for biomarkers (e.g. TARC)

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	3.3%	0%	0%	0%	0%	0%
2	2.3%	12.5%	0%	0%	0%	0%
3	6.6%	12.5%	0%	0%	0%	0%
4	8%	0%	0%	10%	0%	0%
5	12.7%	25%	3.7%	40%	0%	0%
6	17.8%	12.5%	14.8%	20%	50%	50%
7	28.6%	37.5%	48.1%	0%	16.7%	16.7%
8	6.1%	0%	14.8%	10%	0%	0%
9	14.6%	0%	18.5%	20%	33.3%	33.3%

Table 136: FOLLOW UP biorepository samples: collection of biomaterials (e.g. DNA; PBMC; or skin biopsy) for a biorepository

	Doctors	Nurses	Patients	Non-clinical researchers	Industry representatives	Regulatory bodies
1	5.1%	0%	0%	0%	0%	0%
2	3.7%	14.3%	3.7%	0%	0%	0%
3	6%	28.6%	0%	0%	0%	0%
4	8.8%	0%	0%	10%	0%	0%
5	23.5%	28.6%	3.7%	30%	0%	0%
6	13.4%	0%	14.8%	20%	33.3%	33.3%
7	20.3%	28.6%	48.1%	0%	33.3%	33.3%
8	4.6%	0%	7.4%	10%	0%	0%
9	14.7%	0%	22.2%	30%	33.3%	33.3%